When decitabine is used to sustain RIPK3 (a vital factor in inflammation and necroptosis) hypomethylation or FAO targeting in RIPK3-KO mice, the anti-tumor immunity of TAMs is elevated and M2 polarization is attenuated, resulting in FA metabolism suppression [44]. This evidence concerns the gene RIPK3 and neoplasm.